Deals channel feed – Endpoints News

Deals channel feed

TCR-focused Immatics adds another marquee name to its list of partners: GSK

6 years ago

DuPont makes another foray into drug R&D, throwing its name into the microbiome hat

6 years ago

Ligand buys its way into partnership with Roche, CF Foundation — plus some ion channel tech once owned by Pfizer

6 years ago

Bayer hands over a big drug R&D operation to CRO amid an ongoing restructuring effort

6 years ago

Pfizer uncouples from GlycoMimetics and its failed sickle cell disease drug

6 years ago

Moderna eyes $500M secondary offering on upbeat coronavirus vaccine update — almost ready for the clinic

6 years ago

Merck walks away from KalVista, who turns their sights on HAE

6 years ago

It's not just about Keytruda, Merck insists, as it carves out assets worth $6.5B into new company

6 years ago

BioMotiv, Bristol-Myers alliance bears fruit with new company: Anteros Pharma

6 years ago

Catalent chief John Chiminski triggers a $315M-plus wager on the booming cell therapy market now in the making

6 years ago

Following a NASH crash, Conatus turns the keys over to regenerative med player

6 years ago

After a brief break, AstraZeneca is back at divesting — handing off hypertension meds for $350M

6 years ago

AbbVie and Allergan divestitures are in, and an old AstraZeneca drug comes home

6 years ago

Who knew? Dermira’s board kept watch as its stock price tracked Eli Lilly’s secret bidding on a $1.1B buyout

6 years ago

2019 a 'transformative year' for pharma M&A. Is that a good thing?

6 years ago

Amgen augments Asia foothold by taking over Astellas joint venture in Japan

6 years ago

PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

6 years ago

Chicago investor devises £250M deal as real estate grows with UK's biotech sector

6 years ago

In active shopping mode, Eli Lilly plots one deal per quarter as it scouts 'Dermira-like' assets up to $5B

6 years ago

Neon Therapeutics makes one last retreat, selling itself cheap in a bargain basement M&A deal

6 years ago

Galapagos beefs up its fibrosis pipeline, lassoing 4 more programs and taking a stake in small Canadian partner

6 years ago

Still to be approved inclisiran gets red carpet treatment by UK's NHS in deal with Novartis

6 years ago

New Adaptimmune management scores confidence boost with up to $897M+ Astellas deal

6 years ago

Ahead of aducanumab filing, Biogen nabs Pfizer castoff for $75M to address Alzheimer's, Parkinson's symptoms

6 years ago

First page Previous page 94 95 969798 99 100 Next page Last page